(Updates Oct 16 story with company comment in bullet points 4-5) Oct 19 (Reuters) – Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a serious
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
UPDATE 2-As France reels from violence, Macron points to security failings
* Macron declines interior minister's offer to resign * Elysee slams minister for intelligence failures…
China set to leave benchmark lending rates unchanged for 17th month
SHANGHAI, Oct 19 (Reuters) - China is set to leave benchmark lending rates unchanged for…
Light up, lights out? Study dispels myth that weed smokers sleep well
Washington (dpa) - Whatever its merits as a recreational drug or potential medication for pain or…
